Effect of an Intranasal Corticosteroid on Quality of Life and Local Microbiome in Young Children With Chronic Rhinosinusitis
JAMA Pediatrics · 2023
DOI: 10.1001/jamapediatrics.2022.6172 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAMA Pediatrics, 2023. Verfasst von Marta Latek und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Asthma and Allergy, Medical University of Lodz, Lodz, Poland. Hauptthemen laut MEDLINE: Nasal Polyps, Rhinitis, Sinusitis. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Importance Intranasal corticosteroids (INCs) remain the first-line treatment of chronic rhinosinusitis (CRS) in both adults and children, despite the lack of evidence regarding their efficacy in the pediatric population. Similarly, their effect on the sinonasal microbiome has not been well documented.
Objective
To assess the clinical, immunological, and microbiological effects of 12 weeks of an INC in young children with CRS. Design, Setting, and Participants This open-label randomized clinical trial was performed in a pediatric allergy outpatient clinic in 2017 and 2018. Children aged 4 to 8 years with CRS diagnosed by a specialist were included. Data were analyzed from January 2022 to June 2022.
Interventions
Patients were randomized to receive intranasal mometasone in an atomizer for 12 weeks (1 application per nostril, once per day) and supplemental 3-mL sodium chloride (NaCl), 0.9%, solution in a nasal nebulizer once a day for 12 weeks (INC group) or 3-mL NaCl, 0.9%, solution in a nasal nebulizer once a day for 12 weeks (control group). Main Outcomes and Measures Measures taken both before and after treatment included the Sinus and Nasal Quality of Life Survey (SN-5), a nasopharynx swab for microbiome analysis by next-generation sequencing methods, and nasal mucosa sampling for occurrence of innate lymphoid cells (ILCs).
Results
Of the 66 children enrolled, 63 completed the study. The mean (SD) age of the cohort was 6.1 (1.3) years; 38 participants (60.3%) were male and 25 (39.7%) were female. The clinical improvement reflected by reduction in SN-5 score was significantly higher in the INC group compared with the control group (INC group score before and after treatment, 3.6 and 3.1, respectively; control group score before and after treatment, 3.4 and 3.8, respectively; mean between-group difference, −0.58; 95% CI, −1.31 to −0.19; P = .009). The INC group had a greater increase in nasopharyngeal microbiome richness and larger decrease in nasal ILC3 abundance compared with the control group. A significant interaction was observed between change in microbiome richness and the INC intervention on the prediction of significant clinical improvement (odds ratio, 1.09; 95% CI, 1.01-1.19; P = .03). Conclusions and Relevance This randomized clinical trial demonstrated that treatment with an INC improved the quality of life of children with CRS and had a significant effect on increasing sinonasal biodiversity. Although further investigation is needed of the long-term efficacy and safety of INCs, these data may reinforce the recommendation of using INCs as a first-line treatment of CRS in children. Trial Registration ClinicalTrials.gov Identifier: NCT03011632
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Asthma and Allergy, Medical University of Lodz, Lodz, Poland.
- Collegium Medicum, Jan Kochanowski University, Kielce, Poland.
- Cytometry Lab, Department of Molecular Biophysics, University of Lodz, Lodz, Poland.
- Biobank Lab, Department of Molecular Biophysics, University of Lodz, Lodz, Poland.
- Audiology and Phoniatrics Clinic, Nofer Institute of Occupational Medicine, Lodz, Poland.
- Department of Paediatric Otolaryngology, Audiology and Phoniatrics, Medical University of Lodz, Lodz, Poland.
Zitieren
APA
Latek, M., Lacwik, P., Molinska, K., Blauz, A., Lach, J., Rychlik, B., Strapagiel, D., Majak, J., Molinska, J., Czech, D., Seweryn, M., Kuna, P., Palczynski, C., & Majak, P. (2023). Effect of an Intranasal Corticosteroid on Quality of Life and Local Microbiome in Young Children With Chronic Rhinosinusitis. JAMA Pediatrics. https://doi.org/10.1001/jamapediatrics.2022.6172
Vancouver
Latek M, Lacwik P, Molinska K, Blauz A, Lach J, Rychlik B, et al. Effect of an Intranasal Corticosteroid on Quality of Life and Local Microbiome in Young Children With Chronic Rhinosinusitis. JAMA Pediatrics. 2023. doi:10.1001/jamapediatrics.2022.6172
BibTeX
@article{Latek2023,
author = {Latek, Marta and Lacwik, Piotr and Molinska, Katarzyna and Blauz, Andrzej and Lach, Jakub and Rychlik, Blazej and Strapagiel, Dominik and Majak, Joanna and Molinska, Joanna and Czech, Dorota and Seweryn, Michal and Kuna, Piotr and Palczynski, Cezary and Majak, Pawel},
title = {Effect of an Intranasal Corticosteroid on Quality of Life and Local Microbiome in Young Children With Chronic Rhinosinusitis},
journal = {JAMA Pediatrics},
year = {2023},
doi = {10.1001/jamapediatrics.2022.6172}
}
EUVIMED